Videos

Emphasizing the Importance of Breast Cancer Education and Screenings

March 21st 2025, 7:00pm

Video

Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.

The Power of Knowledge and Staying Informed in Breast Cancer Care

March 20th 2025, 8:00pm

Video

Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.

Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer

March 20th 2025, 1:00pm

Video

In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.

How Antibody-Drug Conjugates Have Impacted HER2-Positive Breast Cancer Treatment

March 19th 2025, 8:00pm

Video

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Investigating Quality of Life and Treatment Adherence in Kidney Cancer

March 18th 2025, 7:00pm

Video

Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.

The Role of Circulating Tumor DNA in Breast Cancer Monitoring

March 18th 2025, 1:00pm

Video

Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care.

Precision Radiation Therapy Makes Strides in Colorectal Cancer Care

March 17th 2025, 4:00pm

Video

Dr. Yufei Liu discusses how updates to precision radiation therapy are reshaping colorectal cancer care.

Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease

March 14th 2025, 7:00pm

Video

Dr. Joseph Mikhael discusses the overlooked symptoms of multiple myeloma in honor of Myeloma Awareness Month.

Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma

March 14th 2025, 4:00pm

Video

Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.

What is Late-Line RRMM and How is it Determined?

March 14th 2025, 12:00pm

Video

Panelists discuss how the term "late-line" in relapsed/refractory multiple myeloma typically refers to patients who have progressed through multiple previous treatment regimens, indicating a more advanced disease state that has become resistant to several standard therapeutic approaches.